Skip to main content
Clinical Trials/NCT04909671
NCT04909671
Unknown
Not Applicable

Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome. A Randomized, Parallel, Multicenter, Controlled Trial. TIMELY Study.

Hospital Clinic of Barcelona2 sites in 1 country404 target enrollmentSeptember 13, 2021
ConditionsLynch Syndrome

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lynch Syndrome
Sponsor
Hospital Clinic of Barcelona
Enrollment
404
Locations
2
Primary Endpoint
Mean number of adenomas per colonoscopy
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to assess if artificial intelligence aid colonoscopy colonoscopy is superior to conventional colonoscopy for the detection of adenomas during surveillance colonoscopy in patients with Lynch syndrome.

Detailed Description

To compare the performance of white-light colonoscopy (HD-WLE) versus white-light + CAD (CAD) for detection of adenomas (1:1 ratio). The CAD system will include an artificial intelligence-based medical device (GI Genius, Medtronic) trained to process colonoscopy images and superimpose them, in real time, on the endoscopy display as a green box over suspected lesion. An adequate bowel preparation and minimum withdrawal time of 6 min will be required. Colonoscopies will be performed by experienced endoscopists and with high-definition scopes. Lesions will be collected, and histopathology findings used as the reference standard. The primary outcome of this trial will be the mean number of adenomas per colonoscopy (APC).

Registry
clinicaltrials.gov
Start Date
September 13, 2021
End Date
December 1, 2023
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

María Pellisé

Principal Investigator. Attending physician Gastroenterology department.

Hospital Clinic of Barcelona

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years with a proven pathogenic germline variant in one of the MMR genes (MLH1, MSH2, MSH6) or Epcam deletion who are under surveillance colonoscopy.

Exclusion Criteria

  • Previous history of total colectomy,
  • Concomitant inflammatory bowel disease,
  • Inability or refuse to sign the informed consent,
  • Previous colonoscopy \< 12 months.
  • Inadequate bowel preparation.
  • Incomplete procedure.
  • PMS2 mutation carriers

Outcomes

Primary Outcomes

Mean number of adenomas per colonoscopy

Time Frame: 18 months

Compare mean number of adenomas in both arms calculated by dividing the total number of adenomas detected by the total number of colonoscopies in each arm

Secondary Outcomes

  • Mean number of polyps per colonoscopy(18 months)
  • Withdrawal time(18 months)
  • False positives in CAD arm(18 months)
  • Polyp detection rate(18 months)
  • Adenoma detection rate(18 months)
  • Mean number of non-clinically significant removed lesions(18 months)
  • Subjective endoscopist measures(18 months)

Study Sites (2)

Loading locations...

Similar Trials